PeterAKouidesMD
Hematology • Rochester, NYClotting Disorder, Hemophilia & Bleeding Disorder, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias
Medical and research director, Mary M. Gooley Hemophilia center, Clinical Professor of Medicine University of Rochester School of Medicine
Dr. Kouides is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1425 Portland Ave
Rochester, NY 14621Phone+1 585-922-4020Fax+1 585-563-1832
Summary
- Dr. Peter Kouides is an oncologist in Rochester, NY and is affiliated with Rochester General Hospital. He received his medical degree from State University of New York Upstate Medical University and has been in practice 31 years. He specializes in hematologic oncology and is experienced in thrombotic disorders, bleeding disorders, general / benign hematology, and anemia.
Education & Training
University of RochesterFellowship, Hematology and Medical Oncology, 1989 - 1993
Tufts Medical CenterResidency, Internal Medicine, 1986 - 1989
SUNY Upstate Medical UniversityClass of 1986
Certifications & Licensure
NY State Medical License 1989 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders Start of enrollment: 2003 Apr 01
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome Start of enrollment: 2007 Aug 01
- Von Willebrand Factor in Pregnancy (VIP) Study Start of enrollment: 2019 Oct 12
Publications & Presentations
PubMed
- 41 citationsChanges in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.Elena Holm, Thomas C. Abshire, Joel Bowen, M A Teresa Álvarez, Paula H B Bolton-Maggs
Blood Coagulation & Fibrinolysis. 2015-06-06 - 148 citationsASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.Nathan T. Connell, Veronica H. Flood, Romina Brignardello-Petersen, Rezan Abdul-Kadir, Alice Arapshian
Blood Advances. 2021-01-12 - 8 citationsIs ≥ 100% the magic number to rule out the laboratory diagnosis of von Willebrand disease based on initial testing?Angela C. Weyand, Peter A. Kouides, Jemily Malvar, Julie Jaffray
American Journal of Hematology. 2021-09-16
Abstracts/Posters
- Association of Obesity on Laboratory Profiles of Individuals with Type 1 Von Willebrand Disease and Low VWF in the Athn DatasetPeter A. Kouides, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Discordance between Offsite to Onsite Testing for Von Willebrand Disease in Post-Menarchal Females: A Multi-Center StudyPeter A. Kouides, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular InterventionsPeter A. Kouides, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
